palmitoylethanolamide.com.au
HomeResearchD'Amico 2020

ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain

D'Amico R, Impellizzeri D, Cuzzocrea S, Di Paola R. International Journal of Molecular Sciences, 2020; 21(15):5330.

ReviewHumansOther animals

Design
Review
What was measured
What the evidence shows for palmitoylethanolamide and related ALIAmides in peripheral neuropathic pain: micronised and ultramicronised forms, combinations and newer derivatives

What the authors reported

Clinical trials of several formulations are described in diabetic neuropathy, chemotherapy-related neuropathy, carpal tunnel syndrome, sciatica-type pain and jaw joint pain, with safety and tolerability rated high. The authors call for clinical studies of the newer related compounds in people and in animals.

Limits of this study

A narrative review. The page checked gave no study counts or patient numbers, and the funding and conflict statements were not visible.

Source

doi:10.3390/ijms21155330

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.